Weight Loss Requires Titration

Semaglutide

GLP-1 Receptor Agonist (Ozempic/Wegovy)

Category GLP-1 Agonist
Administration SubQ (Weekly)
Half-Life ~7 days
Target Dose 1.0-2.4mg/week

What is Semaglutide?

Semaglutide is a GLP-1 (glucagon-like peptide-1) receptor agonist that mimics the effects of the natural hormone GLP-1. Originally developed for type 2 diabetes (Ozempic), it has become one of the most effective weight loss medications available (Wegovy).

Unlike most peptides which are research compounds, semaglutide is FDA-approved for both diabetes and weight management. Clinical trials have demonstrated average weight loss of 15-20% of body weight over 68 weeks.

Mechanism of Action

Appetite Suppression

Semaglutide's primary weight loss mechanism is profound appetite reduction:

  • Delayed gastric emptying: Food stays in the stomach longer, promoting fullness
  • CNS effects: Acts on brain regions controlling appetite and food reward
  • Reduced cravings: Many users report decreased interest in food, particularly unhealthy foods

Blood Sugar Regulation

As a GLP-1 agonist, semaglutide also:

  • Stimulates insulin release when blood sugar is elevated
  • Reduces glucagon secretion
  • Improves insulin sensitivity
  • Stabilizes blood sugar levels

Cardiovascular Benefits

Clinical trials have shown cardiovascular benefits including reduced risk of heart attack, stroke, and cardiovascular death in diabetic patients.

Expected Results

Weeks 1-4

Reduced appetite, initial weight loss begins. Side effects most common during this period.

Weeks 4-12

Significant appetite reduction. Weight loss typically 5-8% of starting weight.

Months 3-6

Continued steady weight loss. Most reach 10-15% weight reduction.

6+ Months

Maximum effect reached. Average 15-20% weight loss. Maintenance phase.

Dosing Protocol

Critical: Semaglutide MUST be titrated slowly. Starting at full dose causes severe GI side effects. Follow the escalation schedule below.

Standard Titration Schedule

Weeks Weekly Dose Notes
1-4 0.25 mg Starting dose - assess tolerance
5-8 0.5 mg First increase
9-12 1.0 mg Therapeutic dose for many
13-16 1.7 mg Optional - if needed
17+ 2.4 mg Maximum Wegovy dose

Important Notes

  • Don't skip steps: Each increase allows the body to adapt
  • Stay at a dose: If you have significant side effects, stay at current dose longer before increasing
  • Many stop at 1.0mg: Not everyone needs maximum dose for effective weight loss
  • Consistent day: Pick one day per week and stick to it

Administration

Injection: Subcutaneous, once weekly. Common sites: abdomen, thigh, upper arm. Rotate injection sites.

Timing: Any time of day. Most people choose morning. Can be taken with or without food.

Reconstitution (Research Peptide)

Typical Vial Size: 5mg

Add BAC Water: 2ml

Resulting Concentration: 2.5mg/ml

For 0.25mg dose: 10 units on insulin syringe

For 0.5mg dose: 20 units

For 1.0mg dose: 40 units

Side Effects

GI side effects are common, especially during titration:

Common (usually temporary)

  • Nausea: Most common side effect, usually improves with time
  • Constipation or diarrhea: GI changes are normal
  • Decreased appetite: This is the intended effect
  • Fatigue: Can occur during adaptation
  • Headache: Usually mild

Less Common

  • Injection site reactions: Redness, irritation
  • Heartburn/reflux: Due to delayed gastric emptying
  • Dizziness: Especially if not eating enough

Rare but Serious

  • Pancreatitis: Stop immediately if severe abdominal pain occurs
  • Gallbladder issues: Rapid weight loss can trigger gallstones
  • Thyroid concerns: GLP-1 agonists carry thyroid warnings (based on rodent studies)
Contraindications: Do not use if you have personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Do not use with other GLP-1 agonists.

Semaglutide vs Tirzepatide

Feature Semaglutide Tirzepatide
Mechanism GLP-1 only GLP-1 + GIP dual
Avg Weight Loss 15-17% 20-25%
Max Dose 2.4mg weekly 15mg weekly
FDA Approved Yes (Wegovy/Ozempic) Yes (Zepbound/Mounjaro)
Side Effects GI common Similar GI profile
Cost Lower (generic available) Higher (newer)

Stacking Options

Do NOT combine: Semaglutide should NOT be used with other GLP-1 agonists like Tirzepatide or Liraglutide. Choose one or the other.

Frequently Asked Questions

How long should I take semaglutide?

Semaglutide is meant for long-term use. Studies show weight regain is common after stopping. Many people use it indefinitely or transition to maintenance dosing.

Will I regain weight if I stop?

Studies show approximately 2/3 of weight lost is regained within one year of stopping. Maintaining lifestyle changes helps, but the appetite-suppressing effects will diminish.

Can I drink alcohol on semaglutide?

Alcohol isn't contraindicated but can worsen nausea and may impact blood sugar. Many users find they naturally drink less due to reduced appetite for everything, including alcohol.

What if I miss a dose?

If within 5 days of scheduled dose, take it as soon as remembered. If more than 5 days, skip and take next dose on schedule. Don't double up.

Do I need to diet and exercise?

Semaglutide works without strict dieting due to appetite suppression. However, combining with proper nutrition and exercise produces better results and helps preserve muscle mass during weight loss.

How do I minimize muscle loss?

Prioritize protein intake (0.8-1g per pound of goal body weight), resistance training, and consider slower weight loss. GH peptides may help preserve lean mass.

Medical Supervision: While research-grade semaglutide is available, this is a powerful medication. Consider working with a healthcare provider who can monitor your health, adjust dosing, and watch for complications.